척수성 근위축증(SMA) 치료 시장 보고서(2026년)

Spinal muscular atrophy (SMA) treatment involves medical therapies and interventions focused on managing symptoms, improving muscle strength and motor function, and enhancing the quality of life for individuals with spinal muscular atrophy. SMA is a genetic condition marked by the progressive degeneration of motor neurons in the spinal cord and lower brainstem.

The main treatment types for spinal muscular atrophy include medication, physical therapy, surgery, and other supportive approaches. Medications are used to control symptoms, improve motor function, and slow disease progression. These treatments address various forms of spinal muscular atrophy, including Werdnig-Hoffmann disease, infantile spinal muscular atrophy, Kugelberg-Welander disease, and adult-onset spinal muscular atrophy. Drugs are administered through different routes, such as oral and parenteral, and are distributed via hospital pharmacies, retail pharmacies, and other distribution channels. The key end users include hospitals, homecare settings, specialty clinics, and other healthcare facilities.

Tariffs have impacted the spinal muscular atrophy treatment market by increasing the cost of imported gene therapy drugs, biologics, and specialized medical equipment. Segments such as onasemnogene abeparvovec-xioi (zolgensma) and nusinersen (spinraza) are particularly affected, with North America and Europe experiencing higher costs due to import duties. While tariffs pose challenges in pricing and accessibility, they have also encouraged local manufacturing, regional partnerships, and investment in domestic production capabilities to improve supply chain resilience.

The spinal muscular atrophy treatment market research report is one of a series of new reports from The Business Research Company that provides spinal muscular atrophy treatment market statistics, including spinal muscular atrophy treatment industry global market size, regional shares, competitors with a spinal muscular atrophy treatment market share, detailed spinal muscular atrophy treatment market segments, market trends and opportunities, and any further data you may need to thrive in the spinal muscular atrophy treatment industry. This spinal muscular atrophy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The spinal muscular atrophy treatment market size has grown rapidly in recent years. It will grow from $5.1 billion in 2025 to $5.89 billion in 2026 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to limited therapeutic options for sma, low awareness of genetic disorders, reliance on hospital-based treatment, slow adoption of innovative therapies, lack of early diagnosis programs.

The spinal muscular atrophy treatment market size is expected to see rapid growth in the next few years. It will grow to $10.38 billion in 2030 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to development of advanced gene therapies, rising investment in sma research, increasing newborn screening initiatives, growth of specialty clinics and homecare services, integration of digital health and telemedicine solutions. Major trends in the forecast period include rising adoption of gene therapy and smn2 modifying treatments, increased focus on early diagnosis and newborn screening programs, growth in homecare and specialty clinic-based sma management, expansion of multidisciplinary care teams for sma patients, integration of telehealth and remote patient monitoring.

The increasing emphasis on gene therapy is expected to drive the growth of the spinal muscular atrophy (SMA) treatment market in the coming years. Gene therapy is a medical approach that involves modifying or replacing a patient's genetic material, either DNA or RNA, to treat or prevent disease. The rising focus on gene therapy is largely due to its ability to address the underlying genetic causes of inherited disorders by correcting or compensating for faulty genes, offering the potential for long-term or even permanent therapeutic benefits compared to conventional treatments. Spinal muscular atrophy treatments are well suited to gene therapy approaches, such as onasemnogene abeparvovec (Zolgensma), which provides a one-time, targeted intervention by delivering a functional copy of the SMN1 gene, leading to significant improvements in motor function and quality of life for patients with SMA. For example, in January 2024, according to the American Society of Gene and Cell Therapy, a US-based professional organization, the number of gene therapies in Phase III clinical trials increased by 10% in the fourth quarter of 2023 compared to the previous quarter, marking the first increase since the third quarter of 2022. Therefore, the growing focus on gene therapy is fueling the growth of the spinal muscular atrophy treatment market.

Major companies operating in the spinal muscular atrophy treatment market are concentrating on the development of innovative formulations, such as survival motor neuron 2 (SMN2) splicing modifier tablets, to improve motor function and slow disease progression. SMN2 splicing modifier tablets are oral medications designed to modify the splicing of the SMN2 gene, enabling increased production of functional SMN protein that is essential for motor neuron survival. These therapies help treat SMA by boosting full-length SMN protein levels, thereby improving muscle function and slowing disease progression. For instance, in February 2025, Genentech, Inc., a US-based biotechnology company, received U.S. Food and Drug Administration approval for Evrysdi (risdiplam) tablets, the first non-invasive SMN2 splicing modifier tablet approved for the treatment of SMA. The tablet formulation offers efficacy and safety comparable to the existing oral solution, along with advantages such as room-temperature storage and easier administration for patients aged two years and older who weigh more than 44 pounds (20 kg), providing added convenience and flexibility in disease management.

In January 2024, Voyager Therapeutics Inc., a US-based biotechnology company, entered into a partnership with Novartis to advance gene therapies for neurological diseases. Through this collaboration, Voyager Therapeutics and Novartis aim to discover and develop novel gene therapies for conditions including Huntington's disease and spinal muscular atrophy by combining Voyager's TRACER capsid technology with Novartis's expertise in gene therapy development and commercialization. Novartis is a Switzerland-based pharmaceutical company specializing in treatments for spinal muscular atrophy.

Major companies operating in the spinal muscular atrophy treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Biogen Inc., Ionis Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd, PTC Therapeutics Inc., Voyager Therapeutics Inc., Scholar Rock Holding Corporation, Genethon, Exegenesis Bio Inc., Alcyone Therapeutics Inc., Biophytis SA, Ractigen Therapeutics, Sarepta Therapeutics Inc., Astellas Pharma Inc., Pfizer Inc., AstraZeneca PLC, Roche Molecular Systems Inc., Avexis Inc., Cytokinetics Incorporated, Repligen Corporation, Neurogene Inc., Solid Biosciences Inc., Entrada Therapeutics Inc., Regenxbio Inc., Rocket Pharmaceuticals Inc., Asklepios BioPharmaceutical (AskBio) Inc., Ultragenyx Pharmaceutical Inc., Catalyst Pharmaceuticals Inc., NMD Pharma A/S, Biohaven Pharmaceutical Holding Company Ltd, Vybion Inc., Apteeus SAS, BIOCAD INDIA PRIVATE LIMITED

North America was the largest region in the spinal muscular atrophy treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the spinal muscular atrophy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The spinal muscular atrophy treatment market consists of revenues earned by entities by providing services such as gene delivery services, diagnostic services, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The spinal muscular atrophy treatment market also includes sales of spinraza, zolgensma, evrysdi, and supportive care products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Spinal Muscular Atrophy Treatment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses spinal muscular atrophy treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for spinal muscular atrophy treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The spinal muscular atrophy treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Treatment: Medication; Physical Therapy; Surgery; Other Treatments
• 2) By Type: Werdnig-Hoffmann Disease; Infant Spinal Muscular Atrophy; Kugelberg-Welander Disease; Adult Spinal Muscular Atrophy
• 3) By Route Of Administration: Oral; Parenteral
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Medication: Nusinersen (Spinraza); Onasemnogene Abeparvovec-Xioi (Zolgensma); Risdiplam (Evrysdi); Antisense Oligonucleotides; Spinal Muscular Atrophy (SMN2) Splicing Modifiers; Corticosteroids; Supportive Medications
• 2) By Physical Therapy: Occupational Therapy; Respiratory Therapy; Aquatic Therapy; Orthotic Support; Assistive Mobility Devices; Range-Of-Motion Exercises
• 3) By Surgery: Spinal Fusion Surgery; Scoliosis Correction Surgery; Orthopedic Surgery; Gastrostomy Tube Placement; Tracheostomy
• 4) By Other Treatments: Nutritional Support; Respiratory Support; Psychosocial Support And Counseling; Genetic Counseling; Stem Cell Therapy
• Companies Mentioned: F. Hoffmann-La Roche Ltd; Novartis AG; Biogen Inc.; Ionis Pharmaceuticals Inc.; Chugai Pharmaceutical Co. Ltd; PTC Therapeutics Inc.; Voyager Therapeutics Inc.; Scholar Rock Holding Corporation; Genethon; Exegenesis Bio Inc.; Alcyone Therapeutics Inc.; Biophytis SA; Ractigen Therapeutics; Sarepta Therapeutics Inc.; Astellas Pharma Inc.; Pfizer Inc.; AstraZeneca PLC; Roche Molecular Systems Inc.; Avexis Inc.; Cytokinetics Incorporated; Repligen Corporation; Neurogene Inc.; Solid Biosciences Inc.; Entrada Therapeutics Inc.; Regenxbio Inc.; Rocket Pharmaceuticals Inc.; Asklepios BioPharmaceutical (AskBio) Inc.; Ultragenyx Pharmaceutical Inc.; Catalyst Pharmaceuticals Inc.; NMD Pharma A/S; Biohaven Pharmaceutical Holding Company Ltd; Vybion Inc.; Apteeus SAS; BIOCAD INDIA PRIVATE LIMITED
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Spinal Muscular Atrophy Treatment Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Spinal Muscular Atrophy Treatment Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Spinal Muscular Atrophy Treatment Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Spinal Muscular Atrophy Treatment Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Gene Therapy And SMN2 Modifying Treatments
  • 4.2.2 Increased Focus On Early Diagnosis And Newborn Screening Programs
  • 4.2.3 Growth In Homecare And Specialty Clinic-Based SMA Management
  • 4.2.4 Expansion Of Multidisciplinary Care Teams For SMA Patients
  • 4.2.5 Integration Of Telehealth And Remote Patient Monitoring

5. Spinal Muscular Atrophy Treatment Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Homecare Providers
• 5.3 Specialty Clinics
• 5.4 Genetic Counseling Centers
• 5.5 Rehabilitation Centers

6. Spinal Muscular Atrophy Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Spinal Muscular Atrophy Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Spinal Muscular Atrophy Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Spinal Muscular Atrophy Treatment Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Spinal Muscular Atrophy Treatment Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Spinal Muscular Atrophy Treatment Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Spinal Muscular Atrophy Treatment Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Spinal Muscular Atrophy Treatment Market Segmentation

• 9.1. Global Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Medication, Physical Therapy, Surgery, Other Treatments
• 9.2. Global Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Werdnig-Hoffmann Disease, Infant Spinal Muscular Atrophy, Kugelberg-Welander Disease, Adult Spinal Muscular Atrophy
• 9.3. Global Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Parenteral
• 9.4. Global Spinal Muscular Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
• 9.5. Global Spinal Muscular Atrophy Treatment Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Homecare, Specialty Clinics, Other End Users
• 9.6. Global Spinal Muscular Atrophy Treatment Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Nusinersen (Spinraza), Onasemnogene Abeparvovec-Xioi (Zolgensma), Risdiplam (Evrysdi), Antisense Oligonucleotides, Spinal Muscular Atrophy (SMN2) Splicing Modifiers, Corticosteroids, Supportive Medications
• 9.7. Global Spinal Muscular Atrophy Treatment Market, Sub-Segmentation Of Physical Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Occupational Therapy, Respiratory Therapy, Aquatic Therapy, Orthotic Support, Assistive Mobility Devices, Range-Of-Motion Exercises
• 9.8. Global Spinal Muscular Atrophy Treatment Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Spinal Fusion Surgery, Scoliosis Correction Surgery, Orthopedic Surgery, Gastrostomy Tube Placement, Tracheostomy
• 9.9. Global Spinal Muscular Atrophy Treatment Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Nutritional Support, Respiratory Support, Psychosocial Support And Counseling, Genetic Counseling, Stem Cell Therapy

10. Spinal Muscular Atrophy Treatment Market Regional And Country Analysis

• 10.1. Global Spinal Muscular Atrophy Treatment Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Spinal Muscular Atrophy Treatment Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Spinal Muscular Atrophy Treatment Market

• 11.1. Asia-Pacific Spinal Muscular Atrophy Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Spinal Muscular Atrophy Treatment Market

• 12.1. China Spinal Muscular Atrophy Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Spinal Muscular Atrophy Treatment Market

• 13.1. India Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Spinal Muscular Atrophy Treatment Market

• 14.1. Japan Spinal Muscular Atrophy Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Spinal Muscular Atrophy Treatment Market

• 15.1. Australia Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Spinal Muscular Atrophy Treatment Market

• 16.1. Indonesia Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Spinal Muscular Atrophy Treatment Market

• 17.1. South Korea Spinal Muscular Atrophy Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Spinal Muscular Atrophy Treatment Market

• 18.1. Taiwan Spinal Muscular Atrophy Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Spinal Muscular Atrophy Treatment Market

• 19.1. South East Asia Spinal Muscular Atrophy Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Spinal Muscular Atrophy Treatment Market

• 20.1. Western Europe Spinal Muscular Atrophy Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Spinal Muscular Atrophy Treatment Market

• 21.1. UK Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Spinal Muscular Atrophy Treatment Market

• 22.1. Germany Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Spinal Muscular Atrophy Treatment Market

• 23.1. France Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Spinal Muscular Atrophy Treatment Market

• 24.1. Italy Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Spinal Muscular Atrophy Treatment Market

• 25.1. Spain Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Spinal Muscular Atrophy Treatment Market

• 26.1. Eastern Europe Spinal Muscular Atrophy Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Spinal Muscular Atrophy Treatment Market

• 27.1. Russia Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Spinal Muscular Atrophy Treatment Market

• 28.1. North America Spinal Muscular Atrophy Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Spinal Muscular Atrophy Treatment Market

• 29.1. USA Spinal Muscular Atrophy Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Spinal Muscular Atrophy Treatment Market

• 30.1. Canada Spinal Muscular Atrophy Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Spinal Muscular Atrophy Treatment Market

• 31.1. South America Spinal Muscular Atrophy Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Spinal Muscular Atrophy Treatment Market

• 32.1. Brazil Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Spinal Muscular Atrophy Treatment Market

• 33.1. Middle East Spinal Muscular Atrophy Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Spinal Muscular Atrophy Treatment Market

• 34.1. Africa Spinal Muscular Atrophy Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Spinal Muscular Atrophy Treatment Market Regulatory and Investment Landscape

36. Spinal Muscular Atrophy Treatment Market Competitive Landscape And Company Profiles

• 36.1. Spinal Muscular Atrophy Treatment Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Spinal Muscular Atrophy Treatment Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Spinal Muscular Atrophy Treatment Market Company Profiles
  • 36.3.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Ionis Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Chugai Pharmaceutical Co. Ltd Overview, Products and Services, Strategy and Financial Analysis

37. Spinal Muscular Atrophy Treatment Market Other Major And Innovative Companies

• PTC Therapeutics Inc., Voyager Therapeutics Inc., Scholar Rock Holding Corporation, Genethon, Exegenesis Bio Inc., Alcyone Therapeutics Inc., Biophytis SA, Ractigen Therapeutics, Sarepta Therapeutics Inc., Astellas Pharma Inc., Pfizer Inc., AstraZeneca PLC, Roche Molecular Systems Inc., Avexis Inc., Cytokinetics Incorporated

38. Global Spinal Muscular Atrophy Treatment Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Spinal Muscular Atrophy Treatment Market

40. Spinal Muscular Atrophy Treatment Market High Potential Countries, Segments and Strategies

• 40.1 Spinal Muscular Atrophy Treatment Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Spinal Muscular Atrophy Treatment Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Spinal Muscular Atrophy Treatment Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer